Gold Star Distribution announced a recall of Trojan condoms on December 26, 2025, due to potential rodent exposure. The recall affects several Trojan condom models distributed nationwide, particularly in Minnesota. Consumers should stop using these products immediately and follow the manufacturer's instructions for return and refund.
Potential exposure of rodents and rodent activity in the distribution center.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact GOLD STAR DISTRIBUTION INC or your healthcare provider for instructions. Notification method: Press Release
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall includes various Trojan condom models, including Magnum, Lubricated, Spermicide, Ultra Thin, and Ribbed, among others. The affected products were sold in various packaging sizes, including a 48-count and a 50-count box. Specific UPC codes for affected models include 022600642039 and 022600930501.
The recall stems from potential exposure to rodents and rodent activity in the distribution center. This contamination could pose serious health risks, particularly for users relying on these products for safe sexual practices.
As of the report date, there have been no specific incidents or injuries reported related to this recall. However, the potential for rodent contamination is a significant concern.
Stop using the recalled condom products immediately. Consumers should contact Gold Star Distribution or their healthcare provider for further instructions on how to return the products.
For more details, consumers can contact Gold Star Distribution at the number provided in the recall notification. Additional information is available on the FDA's website.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.